'Pay-for-delay' agreements targeted by China's planned pharma rulebook

By MLex Staff ( August 13, 2024, 08:00 GMT | Insight) -- Brand-name drugmakers are facing regulatory risks with "pay-for-delay" agreements with generic manufacturers, as China's proposed pharmaceutical guidelines classify such deals as potentially violating the country's antitrust law. In a draft released for public consultation late last week, the State Administration for Market Regulation defined pay-for-delay agreements as instances in which brand-name drugmakers provide unjustified compensation to producers of generics in return for their non-compete commitments. The draft rulebook also examined IP issues. Brand-name drugmakers are facing regulatory risks with "pay-for-delay" agreements with generic manufacturers, as China's proposed pharmaceutical guidelines classify such deals as potentially violating the country's antitrust law....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

'Pay-for-delay' agreements targeted by China's planned pharma rulebook

Prepare for tomorrow’s regulatory change, today

Related Sections